SEC Form 4 · accession 0001209191-16-157015
Minerva Neurosciences, Inc. · NERV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Frederick W Ahlholm
Officer — SVP, Chief Accounting Officer
Period of report
Dec 27, 2016
Accepted (ET)
Dec 29, 2016 · 4:41 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001598646
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 27, 2016 | M | 12,000 | $4.71 | A | 22,000 | D | |
| Common StockF2 | Dec 27, 2016 | S | 17,000 | $12.51 | D | 5,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F3 | $4.71 | Dec 27, 2016 | M | 12,000 | D | — | Dec 3, 2025 | Common Stock | 12,000 | 57,000 | D |
Explanation of responses
- F1These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 22, 2016.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.20 - $13.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4.
- F3This option vested as to 25% of the shares on December 4, 2016 and then in quarterly installments over 3 years thereafter.